Development and Validation of a UHPLC-MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib

• Principais autores: Peng-fei Tang (Autor), Su-su Bao (Autor), Nan-yong Gao (Autor), Chuan-feng Shao (Autor), Wei-fei Xie (Autor), Xue-meng Wu (Autor), Le-ping Zhao (Autor), Zhong-xiang Xiao (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Almonertinib was approved for the first-line treatment of advanced NSCLC patients with EGFR-TKI-sensitive genetic mutations by National Medical Products Administration (NMPA) in 2021.The purpose of this study was to establish and validate a fast, accurate, stable and facile ultra-performance liquid...